评估血友病预防策略的有效性 A 管理:现实世界的长度观察研究
Shyh-Shin Chiou1,2,3,4, Ching-Yeh Lin1,5, Te-Fu Weng1,6
1Taiwan Society of Thrombosis and Hemostasis (TSTH) Study Group, Taipei, Taiwan.
Drugs - real world outcomes
|November 20, 2024
概括
中期剂量预防可显著减少严重血友病A (HA) 患者的出血,改善生活质量. 这种预防方法随着时间的推移,证明了成本效益,为管理HA提供了长期的好处.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 血友病A (HA) 管理侧重于控制出血和提高患者的生活质量.
- 调查使用标准半衰期因子VIII (FVIII) 产品的中间剂量预防作为严重HA的预防策略.
研究的目的:
- 评估中剂量FVIII预防在降低出血率方面的有效性.
- 评估预防对严重HA患者生活质量的影响.
- 分析这种预防性治疗策略的成本效益.
主要方法:
- 在台湾进行了一项为期4年的前性纵向研究 (2014-2018),涉及35名没有FVIII抑制剂的严重HA患者.
- 患者从反应性治疗过渡到中间剂量预防.
- 关键指标包括年度出血率 (ABR),年度关节出血率 (AjBR),成本和生活质量指标.
主要成果:
- 在4年后观察到ABR (91.0%) 和AjBR (90.8%) 的显著降低 (p < 0.001).
- 年度FVIII缩剂成本最初增加了41.0%,但由于避免了ABR,证明了成本效益.
- 患者报告生活质量显著改善 (p = 0.036).
结论:
- 中期剂量预防是减少出血和改善严重HA患者生活质量的有效策略.
- 预防性方法在长期内变得具有成本效益,尽管初始成本增加.
- 为决策者提供关于预防治疗严重HA的好处的证据.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469
Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
Retrovirus Life Cycles
45.7K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.7K
Disorders of Hemostasis
710
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
710


